$7.78
3.11% yesterday
NYSE, Nov 17, 10:17 pm CET
ISIN
US37611X1000
Symbol
DNA
Sector
Industry

Ginkgo Bioworks Stock price

$7.78
-5.47 41.28% 1M
-0.31 3.83% 6M
-2.04 20.77% YTD
+1.45 22.91% 1Y
-78.22 90.95% 3Y
-397.02 98.08% 5Y
-397.02 98.08% 10Y
-397.02 98.08% 20Y
NYSE, Closing price Mon, Nov 17 2025
-0.25 3.11%
ISIN
US37611X1000
Symbol
DNA
Sector
Industry

Key metrics

Basic
Market capitalization
$471.4m
Enterprise Value
$9.5m
Net debt
positive
Cash
$461.9m
Shares outstanding
56.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.6 | 2.7
EV/Sales
0.1 | 0.1
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
52.0%
Return on Equity
-76.4%
ROCE
-31.6%
ROIC
-49.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$180.6m | $178.9m
EBITDA
$-278.5m | $-128.3m
EBIT
$-339.5m | $-279.3m
Net Income
$-339.6m | $-294.1m
Free Cash Flow
$-187.2m
Growth (TTM | estimate)
Revenue
-17.1% | -21.2%
EBITDA
23.4% | 69.5%
EBIT
19.9% | 42.2%
Net Income
47.9% | 46.2%
Free Cash Flow
51.7%
Margin (TTM | estimate)
Gross
72.7%
EBITDA
-154.2% | -71.7%
EBIT
-188.0%
Net
-188.0% | -164.4%
Free Cash Flow
-103.6%
More
EPS
$-6.1
FCF per Share
$-3.3
Short interest
15.2%
Employees
834
Rev per Employee
$270.0k
Show more

Is Ginkgo Bioworks a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Ginkgo Bioworks Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Ginkgo Bioworks forecast:

1x Buy
9%
2x Hold
18%
8x Sell
73%

Analyst Opinions

11 Analysts have issued a Ginkgo Bioworks forecast:

Buy
9%
Hold
18%
Sell
73%

Financial data from Ginkgo Bioworks

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
181 181
17% 17%
100%
- Direct Costs 49 49
19% 19%
27%
131 131
26% 26%
73%
- Selling and Administrative Expenses 201 201
48% 48%
111%
- Research and Development Expense 270 270
42% 42%
150%
-278 -278
23% 23%
-154%
- Depreciation and Amortization 61 61
1% 1%
34%
EBIT (Operating Income) EBIT -339 -339
20% 20%
-188%
Net Profit -340 -340
48% 48%
-188%

In millions USD.

Don't miss a Thing! We will send you all news about Ginkgo Bioworks directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ginkgo Bioworks Stock News

Negative
Seeking Alpha
7 days ago
Ginkgo Bioworks shares dropped on Friday as revenue growth continues to disappoint and cash burn persists despite improvements. Q3 results missed expectations, with adjusted revenues tumbling and operating losses jumping thanks to a non-recurring charge taken. DNA's working capital is at its lowest point since coverage began, and recent equity sales have led to over 13% dilution in 18 months.
Neutral
Seeking Alpha
11 days ago
Ginkgo Bioworks Holdings, Inc. ( DNA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Daniel Waid Marshall Jason Kelly - Founder, CEO & Director Steven Coen - Chief Accounting Officer & CFO Presentation Daniel Waid Marshall [Audio Gap] Manager of Communications and Ownership at Ginkgo. I'm joined by Jason Kelly, our Co-Founder and CEO; and Steve Coen, our CFO.
Neutral
PRNewsWire
12 days ago
Ginkgo provides an update on its third quarter financial results BOSTON , Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third quarter ended September 30, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at i...
More Ginkgo Bioworks News

Company Profile

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jason Kelly
Employees 834
Founded 2008
Website investors.ginkgobioworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today